Dipeptidyl-Peptidase IV Inhibitors
"Dipeptidyl-Peptidase IV Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that suppress the degradation of INCRETINS by blocking the action of DIPEPTIDYL-PEPTIDASE IV. This helps to correct the defective INSULIN and GLUCAGON secretion characteristic of TYPE 2 DIABETES MELLITUS by stimulating insulin secretion and suppressing glucagon release.
| Descriptor ID |
D054873
|
| MeSH Number(s) |
D27.505.519.389.745.335 D27.505.696.422.500
|
| Concept/Terms |
Dipeptidyl-Peptidase IV Inhibitors- Dipeptidyl-Peptidase IV Inhibitors
- Dipeptidyl Peptidase IV Inhibitors
- Inhibitors, Dipeptidyl-Peptidase IV
- Gliptins
- Dipeptidyl-Peptidase 4 Inhibitors
- Dipeptidyl Peptidase 4 Inhibitors
|
Below are MeSH descriptors whose meaning is more general than "Dipeptidyl-Peptidase IV Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Dipeptidyl-Peptidase IV Inhibitors".
This graph shows the total number of publications written about "Dipeptidyl-Peptidase IV Inhibitors" by people in this website by year, and whether "Dipeptidyl-Peptidase IV Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2011 | 2 | 0 | 2 |
| 2013 | 0 | 2 | 2 |
| 2014 | 1 | 0 | 1 |
| 2015 | 0 | 1 | 1 |
| 2016 | 1 | 0 | 1 |
| 2018 | 0 | 1 | 1 |
| 2020 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Dipeptidyl-Peptidase IV Inhibitors" by people in Profiles.
-
Bisht P, Bhattacharya A, Pal A, Singh R, Verma SK. Design and synthesis of novel 3,7-dihydro-1H-purine-2,6-diones as DPP-4 inhibitors: An in silico, in vitro and in vivo approach. Eur J Med Chem. 2025 Feb 05; 283:117160.
-
Chang HY, Chou YY, Tang W, Chang GM, Hsieh CF, Singh S, Tung YC. Association of antidiabetic therapies with lower extremity amputation, mortality and healthcare cost from a nationwide retrospective cohort study in Taiwan. Sci Rep. 2021 03 26; 11(1):7000.
-
Gor D, Lee TA, Schumock GT, Walton SM, Gerber BS, Nutescu EA, Touchette DR. Adherence and Persistence with DPP-4 Inhibitors Versus Pioglitazone in Type 2 Diabetes Patients with Chronic Kidney Disease: A Retrospective Claims Database Analysis. J Manag Care Spec Pharm. 2020 Jan; 26(1):67-75.
-
Chang HY, Singh S, Mansour O, Baksh S, Alexander GC. Association Between Sodium-Glucose Cotransporter 2 Inhibitors and Lower Extremity Amputation Among Patients With Type 2 Diabetes. JAMA Intern Med. 2018 09 01; 178(9):1190-1198.
-
Kundu A, Sardar P, Ghosh S, Patel P, Chatterjee S, Meyer TE. Risk of heart failure with dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials. Int J Cardiol. 2016 Jun 01; 212:203-5.
-
Chang HY, Hsieh CF, Singh S, Tang W, Chiang YT, Huang WF. Anti-diabetic therapies and the risk of acute pancreatitis: a nationwide retrospective cohort study from Taiwan. Pharmacoepidemiol Drug Saf. 2015 Jun; 24(6):567-75.
-
Schulte JM, Rothaus CS, Adler JN. Clinical decisions. Management of type 2 diabetes--polling results. N Engl J Med. 2014 Jan 02; 370(1):e2.
-
Jarvis CI, Cabrera A, Charron D. Alogliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes mellitus. Ann Pharmacother. 2013 Nov; 47(11):1532-9.
-
Lapane KL, Yang S, Brown MJ, Jawahar R, Pagliasotti C, Rajpathak S. Sulfonylureas and risk of falls and fractures: a systematic review. Drugs Aging. 2013 Jul; 30(7):527-47.
-
Singh S, Chang HY, Richards TM, Weiner JP, Clark JM, Segal JB. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med. 2013 Apr 08; 173(7):534-9.